Plasmid DNA Purification via Polymer Flocculation and Microfiltration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Scaling up the manufacture and purification of clinical-grade plasmid DNA for large-scale applications is challenging due to high production costs and the need for robust, efficient processes that balance optimization and speed-to-market demands, particularly in polynucleotide vaccine and gene therapy protocols.
Innovation Solution
A novel two-step lysis/lysate clarification process using polymer flocculation followed by a downstream microfiltration-based polishing step, which includes precipitation with polyethylene glycol or alcohols, to isolate and concentrate pharmaceutical-grade plasmid DNA, reducing reliance on expensive chromatographic steps and enhancing process robustness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional chromatographic steps are used for plasmid DNA purification, then purification quality is maintained, but production costs increase
Solution Approach 1:
The patent extracts and eliminates the expensive chromatographic steps from the traditional plasmid DNA purification process, replacing them with alternative methods (anion-exchange chromatography followed by precipitation and filtration) that achieve comparable purification quality at lower cost
Solution Approach 2:
The patent changes the purification approach by using controlled precipitation conditions (polyethylene glycol concentration, temperature, pH) and filtration parameters to achieve high-purity plasmid DNA without relying on expensive chromatographic resins and multiple equilibrium steps
2Productivity
If scaling up plasmid DNA manufacture is implemented, then production volume increases, but process robustness decreases
Solution Approach 1:
The patent segments the purification process into distinct modular steps (lysis, anion-exchange chromatography, precipitation, filtration) that can be independently optimized and controlled, ensuring consistent quality regardless of scale
Solution Approach 2:
The patent employs parameter changes including pH adjustment, temperature control, and controlled addition of precipitating agents to maintain process robustness during scale-up, ensuring reproducible results from laboratory to manufacturing scale
3Loss of time
If speed-to-market is increased, then development time is reduced, but optimization is compromised
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the purification protocol parameters and establishing standardized procedures that can be directly scaled to manufacturing without extensive re-optimization, reducing development time while maintaining process quality
Solution Approach 2:
The patent ensures continuity of useful action by designing a streamlined process with minimal intermediate steps and continuous operation capabilities, reducing development time while maintaining optimization through consistent process parameters throughout the purification sequence
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces production costs and increases process robustness, enabling the scalable and reproducible purification of clinical-grade plasmid DNA, suitable for large-scale applications in vaccines and gene therapy, by effectively clarifying lysates and removing impurities through efficient flocculation and microfiltration.
Implementation Method 1
clarifying the cell lysate by flocculating host cell debris
Implementation Method 2
precipitation of plasmid DNA from a host cell lysate enriched in said DNA
Implementation Method 3
microfiltration of said precipitated DNA under a tangential flow filtration mode
Data Source
AI summary
Methods of isolating clinical-grade plasmid DNA from manufacturing processes, including large-scale fermentation regimes, are disclosed which encompass alternatives to two core unit operations common to plasmid DNA purification processes. The novel upstream and downstream purification processes disclosed herein provide for reduced production costs and increase process robustness. Either or both of the purification processes disclosed herein may be used in combination with additional purification steps known in the art that are associated with DNA plasmid purification technology.